

PRESS RELEASE

Milestone Achievement under License Agreement with Nippon Soda Co., Ltd.

Yokohama, Japan, August 27, 2026 – MabGenesis Inc. (“MabGenesis”), a private biopharmaceutical company headquartered in Yokohama, Japan, and Nippon Soda Co., Ltd. (“Nippon Soda”) today announced that a milestone has been achieved related to the “Licensing of MabGenesis' Therapeutic Antibodies for Feline Inflammatory Diseases,” previously disclosed in a press release on April 28, 2026.

About MabGenesis Inc.

MabGenesis is a startup biopharmaceutical company engaged in the research and development of therapeutic monoclonal antibody drugs. The company possesses the world's highest quality phage display antibody library (MOURA Library) and provides high-quality monoclonal antibodies that are difficult to obtain using conventional technologies. In September 2025, MabGenesis entered into a collaborative research agreement with Nippon Soda for the development of novel monoclonal antibody therapeutics for dogs and cats.

For more information, visit <https://mabgenesis.com/en> and connect with us on [LinkedIn](#).

MabGenesis Inc. press contact

Yuichiro Shibazaki – Chief Business Officer

Email: business@mabgenesis.com

Phone: + 81 80 5926 4677

About Nippon Soda Co., Ltd.

The Company's mission is to create new value through the power of chemistry and increase corporate value by contributing to society. Under this mission, the Company will continue to pursue the creation of new businesses in the animal health field. Through this license acquisition, the Company will advance the development and commercialization of antibody therapeutics for cats, contributing to the resolution of social issues related to animal healthcare.

For more information, visit <https://www.nippon-soda.co.jp/e/>.

Nippon Soda press contacts

Corporate Communication Sec. General Affairs Dept.

Email: info@nissogr.com
